UroGen Pharma Ltd.: shareholders and insiders

URGNNASDAQHealthcare · Pharmaceutical Preparations

Price

$27.65

November 20, 2026Market cap $1.3B

What Ploutos Investor adds for UroGen Pharma

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 10 fiscal years, from 2016
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Insiders and their shares

Purchases and sales by officers and directors from Nov 21, 2025 to Oct 9, 2026, from their own Form 4 filings.

15 Form 4s

Insider trades start on November 29, 2017

Until lately UroGen Pharma was a foreign company listed in the US. Officers of foreign companies do not report their purchases and sales, so there are none before. They are not missing on our side: they were never filed.

  1. Until 2018Foreign company (annual report on 20-F)
  2. February 2019Becomes a US filer (annual report on 10-K)
  3. November 29, 2017The first insider trade report (Form 4)

Bought on the market

–

nobody

Sold on the market

$4.5M

3 people

From Nov 21, 2025 to Nov 21, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan23%
  • The rest77%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 21, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·no buys·sold $4.5M by 3 people

  • 2025: no buys, no sales
  • 2026: no buys, sold $4.5M by 3 people
  • Oct 8, 2026Chris DegnanChief Financial Officer
    Kind
  • Oct 8, 2026Chris DegnanChief Financial Officer
    Kind
  • Sep 8, 2026Mark SchoenbergChief Medical Officer
    Kind
  • Sep 8, 2026Jason Drew SmithGeneral Counsel
    Kind
  • Sep 7, 2026Mark SchoenbergChief Medical Officer
    Kind
  • Sep 7, 2026Jason Drew SmithGeneral Counsel
    Kind
  • Aug 26, 2026James A. Robinson Jr.Director
    Kind
  • Aug 20, 2026Mark SchoenbergChief Medical Officer
    Kind
  • Jul 9, 2026Mark SchoenbergChief Medical Officer
    Kind10b5-1
  • Jun 22, 2026Mark SchoenbergChief Medical Officer
    Kind10b5-1
  • Jun 8, 2026Mark SchoenbergChief Medical Officer
    Kind
  • Jun 8, 2026Mark SchoenbergChief Medical Officer
    Kind
  • May 26, 2026James A. Robinson Jr.Director
    Kind
  • May 8, 2026Mark SchoenbergChief Medical Officer
    Kind10b5-1
  • Feb 3, 2026Jason Drew SmithGeneral Counsel
    Kind
  • Feb 3, 2026Jason Drew SmithGeneral Counsel
    Kind
  • Feb 3, 2026Jason Drew SmithGeneral Counsel
    Kind
  • Feb 3, 2026Mark SchoenbergChief Medical Officer
    Kind
  • Feb 3, 2026Mark SchoenbergChief Medical Officer
    Kind
  • Feb 3, 2026Mark SchoenbergChief Medical Officer
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade. Before May 27, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by URGN's officers and directors from 2017 up to November 20, 2025, 9 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

3 Holders over 5%Oct 27, 2026 Latest filing
  • The Toronto-Dominion Bankwith 1 more person
    Share of class6.70%
  • BlackRock, Inc.
    Share of class6.30%
  • Morgan Stanley
    Share of class5.40%
Fell to 5% or less (7)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • Paradigm BioCapital Advisors LP3.50%May 15, 202613G/A
  • Cowen Financial Products LLC0.00%Nov 14, 202513G/A
  • RA Capital Management, L.P.0.00%Aug 14, 202513G/A
  • Soleus Capital Master Fund, L.P.4.70%Aug 5, 202513G/A
  • Monograph Capital Partners I, L.P.13D1.90%Jun 9, 202513D/A
  • Adage Capital Management, L.P.2.77%May 12, 202513G/A
  • Menora Mivtachim Holdings Ltd4.99%Mar 17, 202513G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Point72 (Cohen)
    In the quarter
  • D.E. Shaw
    In the quarter+12%
  • Millennium Mgmt (Englander)
    In the quarter+152%
  • Citadel Advisors (Griffin)
    In the quarter+175%
  • Renaissance Technologies
    In the quarter-79%
  • AQR Capital
    In the quarter+90%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 11.5% of its shares outstanding were held short, -27.8% since the report before.

Shares held short
5.61M
11.5%
Since the report before7.77M on Sep 30, 2026
-27.8%
4.9
1.14M
More days to cover thanof 4,578 US-listed companies with enough volume
60%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 2.29M
  • Nov 15, 2023: Shares held short 2.83M
  • Nov 30, 2023: Shares held short 2.92M
  • Dec 15, 2023: Shares held short 3.07M
  • Dec 29, 2023: Shares held short 3.55M
  • Jan 12, 2024: Shares held short 3.39M
  • Jan 31, 2024: Shares held short 3.26M
  • Feb 15, 2024: Shares held short 4.01M
  • Feb 29, 2024: Shares held short 3.93M
  • Mar 15, 2024: Shares held short 4.25M
  • Mar 28, 2024: Shares held short 4.19M
  • Apr 15, 2024: Shares held short 4.20M
  • Apr 30, 2024: Shares held short 4.43M
  • May 15, 2024: Shares held short 4.47M
  • May 31, 2024: Shares held short 5.26M
  • Jun 14, 2024: Shares held short 5.62M
  • Jun 28, 2024: Shares held short 6.34M
  • Jul 15, 2024: Shares held short 5.87M
  • Jul 31, 2024: Shares held short 6.10M
  • Aug 15, 2024: Shares held short 6.49M
  • Aug 30, 2024: Shares held short 6.44M
  • Sep 13, 2024: Shares held short 6.37M
  • Sep 30, 2024: Shares held short 7.07M
  • Oct 15, 2024: Shares held short 6.49M
  • Oct 31, 2024: Shares held short 6.60M
  • Nov 15, 2024: Shares held short 6.44M
  • Nov 29, 2024: Shares held short 5.77M
  • Dec 13, 2024: Shares held short 5.81M
  • Dec 31, 2024: Shares held short 5.83M
  • Jan 15, 2025: Shares held short 5.99M
  • Jan 31, 2025: Shares held short 6.16M
  • Feb 14, 2025: Shares held short 6.19M
  • Feb 28, 2025: Shares held short 6.12M
  • Mar 14, 2025: Shares held short 6.15M
  • Mar 31, 2025: Shares held short 5.65M
  • Apr 15, 2025: Shares held short 5.06M
  • Apr 30, 2025: Shares held short 5.02M
  • May 15, 2025: Shares held short 5.59M
  • May 30, 2025: Shares held short 3.92M
  • Jun 13, 2025: Shares held short 6.13M
  • Jun 30, 2025: Shares held short 5.45M
  • Jul 15, 2025: Shares held short 7.29M
  • Jul 31, 2025: Shares held short 7.17M
  • Aug 15, 2025: Shares held short 6.87M
  • Aug 29, 2025: Shares held short 7.02M
  • Sep 15, 2025: Shares held short 7.94M
  • Sep 30, 2025: Shares held short 8.72M
  • Oct 15, 2025: Shares held short 11.15M
  • Oct 31, 2025: Shares held short 11.28M
  • Nov 14, 2025: Shares held short 8.98M
  • Nov 28, 2025: Shares held short 7.95M
  • Dec 15, 2025: Shares held short 7.74M
  • Dec 31, 2025: Shares held short 9.54M
  • Jan 15, 2026: Shares held short 10.57M
  • Jan 30, 2026: Shares held short 10.30M
  • Feb 13, 2026: Shares held short 9.34M
  • Feb 27, 2026: Shares held short 8.02M
  • Mar 13, 2026: Shares held short 8.63M
  • Mar 31, 2026: Shares held short 8.35M
  • Apr 15, 2026: Shares held short 7.83M
  • Apr 30, 2026: Shares held short 7.24M
  • May 15, 2026: Shares held short 6.76M
  • May 29, 2026: Shares held short 6.92M
  • Jun 15, 2026: Shares held short 6.56M
  • Jun 30, 2026: Shares held short 6.22M
  • Jul 15, 2026: Shares held short 5.69M
  • Jul 31, 2026: Shares held short 4.59M
  • Aug 14, 2026: Shares held short 5.12M
  • Aug 31, 2026: Shares held short 6.25M
  • Sep 15, 2026: Shares held short 6.25M
  • Sep 30, 2026: Shares held short 7.77M
  • Oct 15, 2026: Shares held short 5.61M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading60.3% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 60.3% of the shares in the reported trades were short sales, against 56.4% in the 14 before.

Last 14 sessionsNov 3, 2026 – Nov 20, 2026
60.3%
The 14 beforeOct 14, 2026 – Nov 2, 2026
56.4%
Change
+3.9 pts
Short sales a dayon average, of 807.3K shares
487.0K
More than atof 3,666 US-listed companies, same days
83%
Median of alleight in ten from 34.4% to 63.9%
50.5%
  • Oct 14, 2026: Short sales 37.6%
  • Oct 15, 2026: Short sales 47.2%
  • Oct 16, 2026: Short sales 40.2%
  • Oct 19, 2026: Short sales 50.4%
  • Oct 20, 2026: Short sales 60.8%
  • Oct 21, 2026: Short sales 61%
  • Oct 22, 2026: Short sales 49.2%
  • Oct 23, 2026: Short sales 69.8%
  • Oct 26, 2026: Short sales 78%
  • Oct 27, 2026: Short sales 82.8%
  • Oct 28, 2026: Short sales 56.4%
  • Oct 29, 2026: Short sales 45.3%
  • Oct 30, 2026: Short sales 24.9%
  • Nov 2, 2026: Short sales 75.3%
  • Nov 3, 2026: Short sales 73.6%
  • Nov 4, 2026: Short sales 68.9%
  • Nov 5, 2026: Short sales 49.2%
  • Nov 6, 2026: Short sales 36.7%
  • Nov 9, 2026: Short sales 76.6%
  • Nov 10, 2026: Short sales 47.4%
  • Nov 11, 2026: Short sales 40.4%
  • Nov 12, 2026: Short sales 68.3%
  • Nov 13, 2026: Short sales 62%
  • Nov 16, 2026: Short sales 60.8%
  • Nov 17, 2026: Short sales 68.1%
  • Nov 18, 2026: Short sales 65.9%
  • Nov 19, 2026: Short sales 70.4%
  • Nov 20, 2026: Short sales 51.7%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

125.6K Insiders' shares0.26% Of the company
  • Mark SchoenbergChief Medical Officer
    Directly59.9K
  • Jason Drew SmithGeneral Counsel
    Directly53.1K
  • James A. Robinson Jr.Director
    Directly8,000
  • Chris DegnanChief Financial Officer
    Directly4,561

A lower bound: it counts only the 4 officers and directors with a market trade since Nov 22, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

11 ETFs holding it0.35% The largest weight (IWC)
  • IWCiShares Micro-Cap ETF
    Weight in the fund0.35%
  • IBBiShares Biotechnology ETF
    Weight in the fund0.12%
  • FESMFidelity Enhanced Small Cap Core ETF
    Weight in the fund0.11%
  • IWOiShares Russell 2000 Growth ETF
    Weight in the fund0.08%
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.06%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.05%
  • VHTVanguard Health Care Index Fund
    Weight in the fund0.02%
  • SPDWState Street(R) SPDR(R) Portfolio Developed World ex-US ETF
    Weight in the fund0.02%
  • IWNiShares Russell 2000 Value ETF
    Weight in the fund0.01%
  • ONEQFidelity Nasdaq Composite Index ETF
    Weight in the fund0.01%

11 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

190 Managers, Q2 2026$1.6B Value of their positions
  • Q3 2025: Managers 162
  • Q4 2025: Managers 167
  • Q1 2026: Managers 173
  • Q2 2026: Managers 190

Institutional investors by quarter

The fund managers holding URGN, quarter by quarter, from Q2 2017 to Q2 2025, 33 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 190 managers held 42.44M shares, worth $1.6B. During the quarter 40 opened a position, 23 closed one, 60 added and 54 trimmed.

The largest holders, Q2 2026

  • Rtw Investments
    In the quarter
  • BlackRock
    In the quarter+13%
  • Morgan Stanley
    In the quarter+0.6%
  • Kynam Capital Management
    In the quarter+8.3%
  • Jefferies Financial Group
    In the quarter
  • SG Americas Securities
    In the quarter+24%
  • American Century Companies
    In the quarter+2.9%
  • Acorn Capital Advisors
    In the quarter
  • Point72 (Cohen)
    In the quarter
  • Frontier Capital Management
    In the quarter+15%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do UroGen Pharma's filings show?

Who buys and sells is one part of UroGen Pharma's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about URGN's shareholders

Didn't find what you were looking for?

Ask us
Have URGN's insiders bought or sold?

From May 27, 2026 to Oct 9, 2026 UroGen Pharma's insiders bought 0 and sold $3.9M of shares on the market. 19% of the sales were under set 10b5-1 plans.

Which well-known managers hold URGN?

6 of the managers we track held the shares on Sep 30, 2026. The largest position was D.E. Shaw's, worth $52M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.